info@marketresearchfuture.com   📞 +1 (855) 661-4441(US)   📞 +44 1720 412 167(UK)   📞 +91 2269738890(APAC)

SCHEDULE CALL

Nanobody Market Research Report Information by Type (Mono-Specific, and Multi-Specific) by Application [Therapeutic (Cancer, Neurodegenerative Diseases, Infectious Diseases, and Others), Diagnostic (Detection Of Proteins and Microorganisms, Detection Of Small Molecules, and Imaging), Research] , by End User (Pharmaceutical & Biotechnology Companies, Research Laboratories, and Others), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Nanobody Market

Nanobody Market is expected to USD 1.14 billion at a CAGR 24.2% during the forecast period 2022-2030.

Segmentation
By Type Mono-specific and Multi-specific
By Application Therapeutic [Cancer Neurodegenerative Diseases Infectious Diseases and others] Diagnostic [Detection of Proteins and Microorganisms Detection of Small Molecules and Imaging] and Research
By End Users Pharmaceutical & Biotechnology Companies Research Laboratories and Others
Key Players
Companies Profiled   Sanofi S.A. (France)    Merck KGaA (Germany)    Alphamab Oncology (China)   Bristol Myers Squibb (US)    Novartis AG (Switzerland)    GenScript Biotech Corporation (US)    Sensei Biotherapeutics (US)    Beroni Group (Australia)    DiosCURE Therapeutics SE (Germany)    ExeVir Bio BV (Belgium)    Taisho Pharmaceutical Holdings Co Ltd apan)
Drivers
Market Driving Forces    Increasing prevalence of cancer and other chronic diseases    Growing number of clinical trials of various nanobody products and their subsequent approval    Rising R&D activities by biopharmaceutical and pharmaceutical companies
report-list-img No. of Pages: 128
Report Code : MRFR/HC/9539-CR
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

CLIENTS TESTIMONIALS